{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:05:10Z","timestamp":1793837110750,"version":"4.6.1"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["GJPY2415"],"award-info":[{"award-number":["GJPY2415"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472857"],"award-info":[{"award-number":["82472857"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["ZD24-MN"],"award-info":[{"award-number":["ZD24-MN"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117829","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:42:53Z","timestamp":1748637773000},"page":"117829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"296","author":[{"given":"Licheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Change","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin'an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denglong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib2","first-page":"293","article-title":"Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/0008-5472.CAN-24-0133","article-title":"Stimulating soluble guanylyl cyclase with the clinical agonist riociguat restrains the development and progression of castration-resistant prostate cancer","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res."},{"issue":"6564","key":"10.1016\/j.ejmech.2025.117829_bib4","first-page":"216","article-title":"Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis","volume":"374","author":"Pernigoni","year":"2021","journal-title":"Sci. Technol. Humanit."},{"key":"10.1016\/j.ejmech.2025.117829_bib5","article-title":"Advances in the management of castration resistant prostate cancer","volume":"355","author":"Ritch","year":"2016","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.ejmech.2025.117829_bib6","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/0008-5472.CAN-21-0198","article-title":"Bidirectional cross-talk between MAOA and AR promotes hormone-dependent and castration-resistant prostate cancer","volume":"81","author":"Wei","year":"2021","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.ejmech.2025.117829_bib7","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1038\/s41388-018-0198-z","article-title":"Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription","volume":"37","author":"Jia","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.256","article-title":"Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance","volume":"98","author":"Crona","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.neo.2015.05.003","article-title":"Platelet-Synthesized testosterone in men with prostate cancer induces androgen receptor signaling","volume":"17","author":"Zaslavsky","year":"2015","journal-title":"Neoplasia (New York, N. Y.)"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib10","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1158\/1078-0432.CCR-14-2352","article-title":"ERG\/AKR1C3\/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells","volume":"21","author":"Powell","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7714","key":"10.1016\/j.ejmech.2025.117829_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.euf.2021.02.006","article-title":"Emerging prostate-specific membrane antigen-based therapeutics: small molecules, antibodies, and beyond","volume":"7","author":"Nauseef","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.ejmech.2025.117829_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211053898","article-title":"PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?","volume":"13","author":"Giraudet","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13014-018-1037-7","article-title":"Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches","volume":"13","author":"Awang","year":"2018","journal-title":"Radiat. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101833","article-title":"PSMA-Targeted therapy: advancements in detection and treatment modalities with Dr. Scott T. Tagawa","volume":"16","author":"Cortiana","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/RLU.0000000000002212","article-title":"Long-term survival and excellent response to repeated 177Lu-Prostate-Specific membrane antigen 617 radioligand therapy in a patient with advanced metastatic castration-resistant prostate cancer","volume":"43","author":"Roll","year":"2018","journal-title":"Clin. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/RLU.0000000000001591","article-title":"68Ga-PSMA uptake by dermatofibroma in a patient with prostate cancer","volume":"42","author":"Aydin","year":"2017","journal-title":"Clin. Nucl. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117829_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/RLU.0000000000002111","article-title":"Incidental metastatic melanoma identified on 68Ga-Prostate-Specific membrane antigen PET\/CT for metastatic prostate cancer","volume":"43","author":"Snow","year":"2018","journal-title":"Clin. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib19","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/RLU.0000000000002793","article-title":"Heterogeneous 68Ga-Prostate-Specific membrane antigen uptake in the left upper abdomen: mesenchymal tumor","volume":"45","author":"Ar\u00e7ay","year":"2020","journal-title":"Clin. Nucl. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U","article-title":"Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells","volume":"45","author":"Lapidus","year":"2000","journal-title":"Prostate"},{"issue":"470","key":"10.1016\/j.ejmech.2025.117829_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aag3326","article-title":"PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer","volume":"10","author":"Caromile","year":"2017","journal-title":"Sci. Signal."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3892\/ijo.2014.2256","article-title":"Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells","volume":"44","author":"Liu","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2025.117829_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215883","article-title":"Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: first-line imaging is afoot","volume":"548","author":"Jiao","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117829_bib25","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00259-024-06698-7","article-title":"Comparison of discovery rates and prognostic utility of [(68)Ga]Ga-PSMA-11 PET\/CT and circulating tumor DNA in prostate cancer-a cross-sectional study","volume":"51","author":"Kluge","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13148-025-01811-5","article-title":"Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [68Ga]Ga-PSMA-11 PET\/CT study","volume":"17","author":"Kluge","year":"2025","journal-title":"Clin. Epigenet."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.7150\/thno.29884","article-title":"Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer","volume":"9","author":"Shi","year":"2019","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.ejmech.2025.117829_bib28","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117829_bib29","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41181-025-00333-y","article-title":"Hematological toxicity of [(225)Ac]Ac-PSMA-617 and [(177)Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model","volume":"10","author":"Vilangattil","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate Cancer-A review of Current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.ejmech.2025.117829_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164023","article-title":"PSMA theranostics: current landscape and future outlook","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijrobp.2024.08.045","article-title":"Evolving paradigms in prostate cancer: the integral role of prostate-specific membrane antigen positron emission tomography\/computed tomography in primary staging and therapeutic decision-making","volume":"121","author":"Udovicich","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2025.117829_bib35","first-page":"479","article-title":"The role of Ga-68-PSMA PET\/CT in the initial staging of prostate cancer - a single center 4 year experience","volume":"13","author":"P","year":"2021","journal-title":"Res. Rep. Urol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00330-019-06353-y","article-title":"Comparison between pelvic PSMA-PET\/MR and whole-body PSMA-PET\/CT for the initial evaluation of prostate cancer: a proof of concept study","volume":"30","author":"Domachevsky","year":"2020","journal-title":"Eur. Radiol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib37","first-page":"1636","article-title":"Combined targeted radiopharmaceutical therapy and immune checkpoint blockade: from preclinical advances to the clinic","volume":"63","author":"Bellavia","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.23736\/S1824-4785.24.03575-1","article-title":"New target therapies in prostate cancer: from radioligand therapy, to PARP-Inhibitors and immunotherapy","volume":"68","author":"Ceci","year":"2024","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s11912-023-01458-6","article-title":"Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer-combination strategies","volume":"25","author":"Arbuznikova","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2967\/jnumed.120.245456","article-title":"PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study","volume":"62","author":"Weber","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.euf.2021.01.002","article-title":"Prostate-specific membrane antigen-based imaging of castration-resistant prostate cancer","volume":"7","author":"Weber","year":"2021","journal-title":"Eur. Urol. Focus"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2967\/jnumed.120.246603","article-title":"Identification of PCWG3 target populations is more accurate and reproducible with PSMA PET than with conventional imaging: a multicenter retrospective study","volume":"62","author":"Farolfi","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010297","article-title":"PSMA-RLT in patients with metastatic hormone-sensitive prostate cancer: a retrospective study","volume":"15","author":"Banda","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.ejmech.2025.117829_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12227130","article-title":"PSMA PET\/CT in castration-resistant prostate cancer: myth or reality?","volume":"12","author":"Urso","year":"2023","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib47","first-page":"899","article-title":"Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix","volume":"30","author":"Barwe","year":"2007","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib48","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3892\/or.2013.2656","article-title":"Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis","volume":"30","author":"Xu","year":"2013","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/RLU.0000000000005111","article-title":"Prostate-specific membrane antigen PET\/CT detection of prostate cancer metastasis to thyroid and cricoid cartilages","volume":"49","author":"Eichhorn","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41824-025-00241-z","article-title":"Supraclavicular nodal metastasis at primary staging of prostate cancer using (18)F-PSMA-1007 PET\/CT","volume":"9","author":"Gitau","year":"2025","journal-title":"EJNMMI Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/RLU.0000000000004465","article-title":"Isolated liver metastasis detected by 68 Ga-PSMA PET\/CT in newly diagnosed prostate cancer","volume":"48","author":"\u00d6nner","year":"2023","journal-title":"Clin. Nucl. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib52","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/RLU.0000000000004560","article-title":"Asymptomatic prostate cancer metastasis in rectal mucosa revealed by 18 F-PSMA-1007 PET\/CT","volume":"48","author":"Wang","year":"2023","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib53","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1097\/RLU.0000000000003954","article-title":"Thyroid incidentaloma on 68Ga-PSMA-11 PET\/CT leading to detection of thyroid metastasis in metastatic prostate carcinoma","volume":"47","author":"Parghane","year":"2022","journal-title":"Clin. Nucl. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib54","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1097\/RLU.0000000000005228","article-title":"Prostate-specific membrane antigen-avid neurofibroma mimicking cutaneous metastasis in metastatic castration-resistant prostate cancer on 18 F-PSMA-1007 PET\/CT","volume":"49","author":"Aggarwal","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib55","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2967\/jnumed.119.233312","article-title":"PET imaging quantifying (68)Ga-PSMA-11 uptake in metastatic colorectal cancer","volume":"61","author":"Cuda","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/med.21508","article-title":"Targeting prostate cancer: prostate-specific membrane antigen based diagnosis and therapy","volume":"39","author":"W\u00fcstemann","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib57","article-title":"Prostate-specific membrane antigen positron emission tomography oncological applications beyond prostate cancer in comparison to other radiopharmaceuticals","volume":"14","author":"Miceli","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22040523","article-title":"Metal-based PSMA radioligands","volume":"22","author":"Gourni","year":"2017","journal-title":"Molecules"},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.117829_bib59","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2016.08.048","article-title":"Discovery of PSMA-Specific peptide ligands for targeted drug delivery","volume":"513","author":"Jin","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res."},{"issue":"33","key":"10.1016\/j.ejmech.2025.117829_bib61","article-title":"Genetically engineered membrane-coated nanoparticles for enhanced prostate-specific membrane antigen targeting and ferroptosis treatment of castration-resistant prostate cancer","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib62","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-020-05169-z","article-title":"[(18)F]-JK-PSMA-7 and [(18)F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice","volume":"48","author":"Van Simaeys","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib63","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1007\/s00259-021-05298-z","article-title":"Stereotactic radiotherapy to oligoprogressive lesions detected with (68)Ga-PSMA-PET\/CT in castration-resistant prostate cancer patients","volume":"48","author":"Onal","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117829_bib64","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.molpharmaceut.0c00457","article-title":"Development of 5D3-DM1: a novel anti-prostate-specific membrane antigen antibody-drug conjugate for PSMA-positive prostate cancer therapy","volume":"17","author":"Huang","year":"2020","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.262250","article-title":"The added value of (18)F-FDG PET\/CT compared to (68)Ga-PSMA PET\/CT in patients with castration-resistant prostate cancer","volume":"63","author":"Chen","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib66","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3760\/cma.j.issn.0366-6999.20132707","article-title":"Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase\/Akt signaling pathway","volume":"127","author":"Guo","year":"2014","journal-title":"Chin. Med. J. (Engl. Ed.)"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib67","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10753-012-9586-7","article-title":"The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells","volume":"36","author":"Ben","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2025.117829_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","article-title":"AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Vanwelkenhuyzen","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2024.09.005","article-title":"Molecular hallmarks of prostate-specific membrane antigen in treatment-na\u00efve prostate cancer","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib70","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/JU.0000000000002457","article-title":"Imaging prostate cancer: clinical utility of prostate-specific membrane antigen","volume":"207","author":"Kuppermann","year":"2022","journal-title":"J. Urol."},{"key":"10.1016\/j.ejmech.2025.117829_bib71","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2023.10.038","article-title":"Membrane-derived particles shed by PSMA-positive cells function as pro-angiogenic stimuli in tumors","volume":"364","author":"Machado","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2025.117829_bib72","article-title":"Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117829_bib73","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1007\/s00259-023-06355-5","article-title":"Total-body [(68) Ga]Ga-PSMA-11 PET\/CT improves detection rate compared with conventional [(68) Ga]Ga-PSMA-11 PET\/CT in patients with biochemical recurrent prostate cancer","volume":"50","author":"Wang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13550-024-01076-8","article-title":"The image quality and feasibility of solitary delayed [(68) Ga]Ga-PSMA-11 PET\/CT using long field-of-view scanning in patients with prostate cancer","volume":"14","author":"Yu","year":"2024","journal-title":"EJNMMI Res."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib75","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00259-024-06980-8","article-title":"Comparison of clinical performance between late and standard total-body [(68) Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer","volume":"52","author":"Chen","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117829_bib76","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00066-018-1291-5","article-title":"The impact of [(68)Ga]PSMA I&T PET\/CT on radiotherapy planning in patients with prostate cancer","volume":"194","author":"Frenzel","year":"2018","journal-title":"Strahlenther. Onkol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib77","article-title":"Review of Gallium-68 PSMA PET\/CT imaging in the management of prostate cancer","volume":"8","author":"Lenzo","year":"2018","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13050722","article-title":"Efficacy and safety of [(225)Ac]Ac-PSMA-617 augmented [(177)Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis","volume":"13","author":"Rosar","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib79","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative (68)Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following (177)Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib80","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [(68)Ga]Ga-\/[(18)F]F-PSMA-11\/-1007, [(68)Ga]Ga-FAPI-46 and 2-[(18)F]FDG PET\/CT: a pilot study","volume":"52","author":"Pabst","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117829_bib81","article-title":"Salivary gland toxicity of PSMA-targeted radioligand therapy with (177)Lu-PSMA and combined (225)Ac- and (177)Lu-Labeled PSMA ligands (TANDEM-PRLT) in advanced prostate cancer: a single-center systematic investigation","volume":"12","author":"Langbein","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117829_bib82","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.7150\/thno.56211","article-title":"Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617\/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy","volume":"11","author":"Rosar","year":"2021","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib83","first-page":"248","article-title":"Prostate-specific membrane antigen PET in","volume":"299","author":"Lawhn-Heath","year":"2021","journal-title":"Prostate Cancer. Radiol."},{"key":"10.1016\/j.ejmech.2025.117829_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231213618","article-title":"Clinical practice in prostate PET imaging","volume":"15","author":"Huls","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib85","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/01.ju.0000091655.77601.0c","article-title":"Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen","volume":"170","author":"Bander","year":"2003","journal-title":"J. Urol."},{"issue":"6 Pt 2","key":"10.1016\/j.ejmech.2025.117829_bib86","first-page":"S84","article-title":"Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen","volume":"170","author":"Nanus","year":"2003","journal-title":"J. Urol."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117829_bib87","first-page":"5237","article-title":"In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen","volume":"60","author":"Smith-Jones","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib88","first-page":"610","article-title":"Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor","volume":"44","author":"Smith-Jones","year":"2003","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib89","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-21-0496","article-title":"IL15 and Anti-PD-1 augment the efficacy of agonistic intratumoral Anti-CD40 in a mouse model with multiple TRAMP-C2 tumors","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib90","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity","volume":"51","author":"Katoh","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117829_bib91","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1158\/0008-5472.CAN-20-1624","article-title":"Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer advantages for targeted cancer therapies","volume":"81","author":"Matthias","year":"2021","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.ejmech.2025.117829_bib92","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1158\/1078-0432.CCR-21-0342","article-title":"Darolutamide potentiates the antitumor efficacy of a PSMA-Targeted Thorium-227 conjugate by a dual mode of action in prostate cancer models","volume":"27","author":"Hammer","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib93","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/acs.bioconjchem.8b00767","article-title":"Synthesis and evaluation of multifunctional fluorescent inhibitors with synergistic interaction of prostate-specific membrane antigen and hypoxia for prostate cancer","volume":"30","author":"Kwon","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117829_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112099","article-title":"Novel multifunctional (18)F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties","volume":"189","author":"Kwon","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib95","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/1541-7786.MCR-23-0075","article-title":"A novel role of prostate-specific membrane antigen in telomere stability in prostate cancer cells","volume":"21","author":"Reddy","year":"2023","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117829_bib96","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-Targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117829_bib97","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1021\/acs.molpharmaceut.1c00711","article-title":"Evaluation of (177)Lu and (47)Sc picaga-linked, prostate-specific membrane antigen-targeting constructs for their radiotherapeutic efficacy and dosimetry","volume":"18","author":"Vaughn","year":"2021","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00262-007-0348-6","article-title":"A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells","volume":"57","author":"B\u00fchler","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib99","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00262-006-0131-0","article-title":"A recombinant PSMA-Specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells","volume":"55","author":"Wolf","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115501","article-title":"A single-domain antibody-based Anti-PSMA recombinant immunotoxin exhibits specificity and efficacy for prostate cancer therapy","volume":"22","author":"Xing","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib101","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1590\/s1677-5538.ibju.2020.0986","article-title":"Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Hu","year":"2022","journal-title":"Int. Braz. J. Urol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117829_bib102","article-title":"(68)Ga-PSMA PET\/CT in recurrent prostate cancer after radical prostatectomy using PSMA-RADS version 2.0","volume":"14","author":"Masselli","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ejmech.2025.117829_bib103","series-title":"Diagnostic Performance of 18F-prostate-specific Membrane Antigen-1007 PET\/CT in the Detection of Prostate Cancer","year":"2020"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib104","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11307-020-01546-0","article-title":"[(18)F]-JK-PSMA-7 PET\/CT under androgen deprivation therapy in advanced","volume":"23","author":"Dietlein","year":"2021","journal-title":"Prostate Cancer. Mol. Imaging Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib105","first-page":"183","article-title":"Clinical factors associated with suspicious (18)F-DCFPyL prostate-specific membrane antigen positron emission tomography activity in patients initially managed with radical prostatectomy including prostate-specific antigen < 0.5 ng\/mL","volume":"213","author":"Li","year":"2025","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib106","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.euf.2023.03.023","article-title":"Diagnostic performance of (68)Ga-PSMA-11 positron emission tomography\/computed tomography to monitor treatment response in patients with metastatic prostate cancer: the concordance between biochemical response and prostate-specific membrane antigen results","volume":"9","author":"Esen","year":"2023","journal-title":"Eur. Urol. Focus"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117829_bib107","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1007\/s00259-024-06674-1","article-title":"The superior detection rate of total-body [(68)Ga]Ga-PSMA-11 PET\/CT compared to short axial field-of-view [(68)Ga]Ga-PSMA-11 PET\/CT for early recurrent prostate cancer patients with PSA < 0.2 ng\/mL after radical prostatectomy","volume":"51","author":"Wang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117829_bib108","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/RLU.0000000000001197","article-title":"68Ga-PSMA-PET\/CT in patients with biochemical prostate cancer recurrence and negative 18F-Choline-PET\/CT","volume":"41","author":"Bluemel","year":"2016","journal-title":"Clin. Nucl. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117829_bib109","doi-asserted-by":"crossref","DOI":"10.1148\/rg.240080","article-title":"PSMA radiotheranostics in prostate cancer: principles, practice, and future prospects","volume":"44","author":"Szidonya","year":"2024","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol. Diagn. Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1158\/2159-8290.CD-NB2019-028","article-title":"Radionuclide treatment yields responses in mCRPC","volume":"9","year":"2019","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib112","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.12.002","article-title":"Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with (225)Ac-PSMA-617 targeted alpha-radiation therapy","volume":"39","author":"van der Doelen","year":"2021","journal-title":"Urol. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117829_bib114","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising Lutetium-177 and Actinium-225 in metastatic prostate cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib115","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.123.265878","article-title":"Improved quality of life in metastatic castration-resistant prostate cancer patients receiving consecutive cycles of (177)Lu-PSMA I&T","volume":"64","author":"Karimzadeh","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117829_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.835956","article-title":"Lu-PSMA-I&T radioligand therapy for treating metastatic castration-resistant prostate cancer: a single-centre study in east Asians","volume":"12","author":"Bu","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib117","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1021\/acs.molpharmaceut.7b01024","article-title":"Improvement in therapeutic efficacy and reduction in cellular toxicity: introduction of a novel Anti-PSMA-Conjugated hybrid antiandrogen nanoparticle","volume":"15","author":"Thangavel","year":"2018","journal-title":"Mol. Pharm."},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2025.117829_bib118","article-title":"A nanoprodrug derived from branched poly (ethylene glycol) recognizes prostate-specific membrane antigen to precisely suppress prostate cancer progression","volume":"282","author":"Guo","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib119","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pros.23124","article-title":"Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer","volume":"76","author":"DiPippo","year":"2016","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib120","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.7150\/thno.68715","article-title":"A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib121","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.123.266391","article-title":"Differences and common ground in (177)Lu-PSMA radioligand therapy practice patterns: international survey of 95 Theranostic centers","volume":"65","author":"Farolfi","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib122","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"(68)Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117829_bib123","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1248\/cpb.c20-00017","article-title":"Bone-Targeted drug delivery systems and strategies for treatment of bone metastasis","volume":"68","author":"Katsumi","year":"2020","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejmech.2025.117829_bib124","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-025-01323-7","article-title":"Advances in targeted therapy for metastatic prostate cancer","author":"Grewal","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117829_bib125","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/pros.24237","article-title":"PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state","volume":"81","author":"Watanabe","year":"2021","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117829_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092244","article-title":"More than meets the eye: scientific rationale behind molecular imaging and therapeutic targeting of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer and beyond","volume":"13","author":"Hyv\u00e4kk\u00e4","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117829_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122894","article-title":"Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy","volume":"315","author":"Gao","year":"2025","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-Checkpoint blockade enhances (225)Ac-PSMA617 efficacy in a mouse model of prostate cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib129","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/mt.2011.145","article-title":"Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers","volume":"19","author":"Pastor","year":"2011","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib130","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1002\/jcb.28370","article-title":"Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer","volume":"120","author":"Hassani","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib131","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/RLU.0000000000005028","article-title":"Incidental prostate-specific membrane antigen-avid vestibular schwannoma detected on 68 ga-prostate-specific membrane antigen PET\/CT","volume":"49","author":"Chen","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib132","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of (18)F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051359","article-title":"Recent advances in prostate cancer treatment and drug discovery","volume":"19","author":"Nevedomskaya","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib134","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13550-023-01009-x","article-title":"Impact of non-regional lymph node metastases accurately revealed on (18)F-PSMA-1007 PET\/CT in the clinical management of metastatic hormone-sensitive prostate cancer","volume":"13","author":"Jiang","year":"2023","journal-title":"EJNMMI Res."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117829_bib135","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","article-title":"Performance of [(68)Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients","volume":"48","author":"Afshar-Oromieh","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib136","article-title":"Current status of neoadjuvant treatment before surgery in high-risk localized prostate cancer","volume":"17","author":"G\u00f3mez","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.ejmech.2025.117829_bib137","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.7150\/thno.44584","article-title":"Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET","volume":"10","author":"Ferraro","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib138","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","article-title":"Flare on [(18)F]PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients","volume":"50","author":"Malaspina","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061898","article-title":"Comparison of hormone-sensitive oligorecurrent prostate cancer patients based on routine use of choline and\/or PSMA PET\/CT to guide metastasis-directed therapy","volume":"15","author":"Metz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijrobp.2018.08.066","article-title":"Patterns of progression after (68)Ga-PSMA-Ligand PET\/CT-Guided radiation therapy for recurrent","volume":"103","author":"Soldatov","year":"2019","journal-title":"Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib141","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2025.117829_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110443","article-title":"Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics","volume":"199","author":"Cao","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12052011","article-title":"Difficulties in defining oligometastatic prostate cancer: implications for clinical trial accrual and community practice adoption of metastasis-directed therapy approaches","volume":"12","author":"Dorff","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib144","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2017.12.008","article-title":"Efficacy against human prostate cancer by prostate-specific membrane antigen-specific, transforming growth Factor-\u03b2 Insensitive genetically targeted CD8(+) T-cells derived from patients with metastatic castrate-resistant disease","volume":"73","author":"Zhang","year":"2018","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005383","article-title":"First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer","volume":"10","author":"Digklia","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"22","key":"10.1016\/j.ejmech.2025.117829_bib146","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1073\/pnas.1735443100","article-title":"The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy","volume":"100","author":"Sch\u00fclke","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117829_bib147","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1097\/RLU.0000000000004781","article-title":"Excellent response to full-dose 177 Lu-PSMA-617 RLT in metastatic castration-resistant prostate cancer with transplant kidney : a step ahead","volume":"48","author":"Mahdi","year":"2023","journal-title":"Clin. Nucl. Med."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117829_bib148","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1158\/1078-0432.CCR-21-3858","article-title":"CUB domain-containing protein 1 (CDCP1) is a target for radioligand therapy in castration-resistant prostate cancer, including PSMA null disease","volume":"28","author":"Zhao","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117829_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00906-z","article-title":"Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey","author":"McManus","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejmech.2025.117829_bib150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","article-title":"The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far","volume":"98\u201399","author":"Heynickx","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.117829_bib151","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202415322","article-title":"PSMA-Targeted nanoparticles with PI3K\/mTOR dual inhibitor downregulate P-Glycoprotein and inactivate myeloid-derived suppressor cells for enhanced chemotherapy and immunotherapy in prostate cancer","author":"Yin","year":"2025","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib152","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-Specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes","volume":"85","author":"Corpetti","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2025.117829_bib153","article-title":"PSMA-RADS to improve evaluation and management of prostate cancer","author":"Rafiei","year":"2024","journal-title":"Abdom. Radiol. (NY)"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib154","article-title":"Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient","volume":"10","author":"Aras","year":"2021","journal-title":"Acta Radiol. Open"},{"key":"10.1016\/j.ejmech.2025.117829_bib155","article-title":"PSMA-RADS to improve evaluation and management of prostate cancer","author":"Rafiei","year":"2024","journal-title":"Abdom. Radiol. (NY)"},{"key":"10.1016\/j.ejmech.2025.117829_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116581","article-title":"Simultaneous targeting and monitoring of free antigen and in-situ membrane antigen in prostate cancer cells via an aggregation-induced emission-based bifunctional probe","volume":"263","author":"Wang","year":"2024","journal-title":"Biosens. Bioelectron."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117829_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212095","article-title":"Prostate-Specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer","volume":"22","author":"Plichta","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib158","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","article-title":"PSMA PET and radionuclide therapy in prostate cancer","volume":"46","author":"Bouchelouche","year":"2016","journal-title":"Semin. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020315","article-title":"PSMA-Targeted nanotheranostics for imaging and radiotherapy of prostate cancer","volume":"16","author":"Meher","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117829_bib160","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2967\/jnumed.118.218917","article-title":"Dosimetry estimate and initial clinical experience with (90)Y-PSMA-617","volume":"60","author":"Rathke","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2025.117829_bib161","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-Based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience since 2013","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117829_bib162","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","article-title":"Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies","volume":"23","author":"Iravani","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117829_bib163","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/RLU.0000000000001763","article-title":"Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer","volume":"42","author":"Wei","year":"2017","journal-title":"Clin. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117829_bib164","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.119.233429","article-title":"Additional local therapy for liver metastases in patients with metastatic castration-resistant prostate cancer receiving systemic PSMA-Targeted therapy","volume":"61","author":"Seifert","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117829_bib165","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","article-title":"(177)Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy","volume":"46","author":"Banerjee","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117829_bib166","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-024-06959-5","article-title":"Experience of rescue therapy with [(177)Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [(177)Lu]Lu-PSMA-I&T","volume":"52","author":"G\u00e4ble","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117829_bib167","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","article-title":"Investigating PSMA-Targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity","volume":"26","author":"Current","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117829_bib168","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16111974","article-title":"From despair to hope: first Arabic experience of (177)Lu-PSMA and (161)Tb-PSMA therapy for metastatic castration-resistant prostate cancer","volume":"16","author":"Al-Ibraheem","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117829_bib169","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.euf.2020.09.005","article-title":"Prostate-specific membrane antigen imaging and theranostics impact patient outcomes","volume":"7","author":"Hadaschik","year":"2021","journal-title":"Eur. Urol. Focus"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500594X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500594X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:37:16Z","timestamp":1754987836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500594X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":169,"alternative-id":["S022352342500594X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117829","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117829"}}